RPP

24-08-mRNALongTerm_Final The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) aimed at vaccine development and response for emerging infectious diseases and rapid pandemic influenza. The RPP, numbered RRPV-24-08-mRNALongTerm, focuses on creating a lasting partnership that builds and maintains a robust mRNA preparedness and response system for pandemic influenza

RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines

BARDA RRPV 24-03-SmMol The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) under the Rapid Response Partnership Vehicle (RRPV) for developing small molecule therapeutics aimed at COVID-19 Pre-exposure Prophylaxis (PrEP). This initiative enhances national health security by advancing medical countermeasures against SARS-CoV-2 and future health threats. BARDA’s call

BioMaP_RPP_24-05-N95 The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at sustaining the manufacturing capacity of N95 respirators, a crucial element in the biopharmaceutical and healthcare sectors, especially highlighted during the COVID-19 pandemic. The RPP, numbered 24-05-N95, focuses on maintaining a “warm-base” status of manufacturing capabilities

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Project Proposals (RPP) for “Manufacturing Optimization for Filovirus Monoclonal Antibodies.” The RPP was released on June 24, 2024, with proposals due by July 22, 2024. This initiative aims to enhance the manufacturing development of monoclonal antibody (mAb) cocktails targeting filoviruses like Ebola and Marburg viruses.